-+ 0.00%
-+ 0.00%
-+ 0.00%

HLB PEP Signs 666 Million Won Drug Production Contract With Skinmed

PUBT·11/20/2026 07:21:06
HLB PEP Signs 666 Million Won Drug Production Contract With Skinmed
  • HLB PEP signed a KRW 666 million contract with Skinmed on Nov. 19, 2026.
  • The deal covers contract development and manufacturing of active pharmaceutical ingredients for Phase 2 clinical trials.
  • The contract represents 13.42% of annual revenue.
  • The contract runs from Nov. 19, 2026, through Sept. 30, 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLB PEP Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261120900631), on November 20, 2026, and is solely responsible for the information contained therein.